Table 2.
Patient characteristics
| Patient | Age | Stage | Surgery | No. of lymph nodes dissected | Size of largest lymph node (cm) | Involved lymph node levels | ECE+ | Receptor status | Neoadjuvant chemotherapy |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| 1 | 35 | cT2N1/ypT0N0 | BCS | 5 | 1.4 | I, II | N | ER−/PR−/H2N− | ACT |
| 2 | 51 | cT3N1/ypT2N1c | MRM | 4 | 2.3 | I, II | N | ER+/PR+/H2N− | ACT |
| 3 | 47 | cT3N1/ypTisN0 | MRM | 16 | 1.2 | I | N | ER+/PR+/H2N+ | TH, abraxane, FECH |
| 4 | 73 | cT3N1/ypT1cN2a | MRM | 14 | 2.2 | I, II | Y | ER+/PR+/H2N− | ACT |
| 5 | 57 | cT3N1/ypT0N1a | MRM | 8 | 6.3 | I, II, III | Y | ER−/PR−/H2N− | ACT |
| 6 | 49 | cT2N1/ypT1cN2a | BCS | 15 | 1 | I, II | N | ER+/PR−/H2N− | ACT |
| 7 | 47 | cT2N1/ypT3N1a | MRM | NS | 6.2 | I, II, III | Y | ER+/PR+/H2N− | ACT |
| 8 | 52 | cT3N3c*/ypT1N1a | MRM | 11 | 1.8 | I, II, SCV | N | ER−/PR−/H2N+ | ACTH |
| 9 | 48 | cT3N1/ypT3N0 | MRM | 9 | 4.4 | I, II, III | N | ER−/PR−/H2N− | ACT |
| 10 | 52 | cT4aN1/ypT3N0 | BCS | 5 | 1 | I, II, III | N | ER−/PR−/H2N− | ACT |
| 11 | 38 | cT4aN1/ypT2N0 | MRM | 4 | 1.9 | I, II, III | N | ER−/PR+/H2N− | ACT |
| 12 | 53 | cT3N1/ypT1aN0 | MRM | 20 | 1.5 | I, II | N | ER+/PR−/H2N+ | ACTH |
| 13 | 62 | cT1cN2a/ypT0N0 | BCS | 15 | 1.7 | I, II, III | N | ER+/PR−/H2N− | ACT |
| 14 | 54 | cT2N1/ypT1cN3a | BCS | 19 | 2.3 | I, II | Y | ER−/PR−/H2N− | ACT |
| 15 | 56 | cT3N1/ypT0N0 | BCS | 11 | 2.6 | I, II, III | N | ER−/PR−/H2N+ | ACTH |
| 16 | 50 | cT4dN1/ypT2N3a | MRM | 19 | 2.2 | I, II | Y | ER+/PR+/H2N− | ACT |
| 17 | 47 | cT4dN1/ypTisN0 | MRM | 13 | 2.2 | I, II | N | ER−/PR−/H2N+ | CTH |
| 18 | 52 | cT4dN1/ypT1bN1mic | MRM | 18 | 1.8 | I, II, III | N | ER−/PR−/H2N− | TC |
| 19 | 37 | cT4dN1/ypT0N1 | MRM | 24 | 2.3 | I, II, III | N | ER−/PR−/H2N+ | ACTH |
| 20 | 67 | cT2N3c*/ypT2N2a | MRM | 9 | 1.2 | I, II, SCV, IM | N | ER−/PR−/H2N− | ACT |
| 21 | 70 | cT2N3c*/ypT1aN2 | BCS | 36 | 5 | I, II, SCV | N | ER−/PR−/H2N− | Carboplatin/eribulin |
| 22 | 73 | cT4dN1M1 | n/a | n/a | 2 | I, II | n/a | ER+/PR−/H2N+ | CMFH, gemcitabine |
| 23 | 58 | cT4dN1M1 | n/a | n/a | 1.5 | I, II, III | n/a | ER+/PR−/H2N+ | ACT |
| 24 | 62 | cT4dN1M1 | n/a | n/a | 1 | I, II | n/a | ER−/PR−/H2N+ | TH |
| 25 | 26 | cT4dN1/ypT0N0 | MRM | 15 | 2.8 | I, II | N | ER−/PR−/H2N+ | CTH |
| 26 | 62 | cT2N1/ypT0N0 | BCS | 3 | 1.1 | I, II, III | N | ER−/PR−/H2N− | ACT |
| 27 | 49 | cT4aN1/ypT1bN2a | BCS | 12 | 5.3 | I, II | Y | ER+/PR−/H2N− | ACT |
| 28 | 60 | cT2N1/ypTisN2a | BCS | 20 | 2.8 | I | Y | ER+/PR+/H2N− | ACT |
| 29 | 34 | cT2N3b/ypT0N0 | BCS | 18 | 1.7 | I, II | N | ER−/PR+/H2N+ | TCH |
| 30 | 37 | cT2N1/ypT0N1mic | BCS | 11 | 1.2 | I, II | N | ER+/PR−/H2N− | ACT |
Abbreviations: ACT = doxorubicin/cyclophosphamide/paclitaxel; BCS = breast conservation surgery; CMF = cyclophosphamide/methotrexate/ fluorouracil; ECE = extracapsular extension; ER = estrogen receptor; FEC = fluorouracil/epirubicin/cyclophosphamide; H = Herceptin; H2N = HER2/neu; IM = internal mammary; LRR = local-regional recurrence; MRM = modified radical mastectomy; n/a = not applicable; PR = progesterone receptor; SCV = supraclavicular.